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THE PROMISE AND PERIL OF DIRECT-TO-
CONSUMER PRESCRIPTION DRUG PROMOTION
ON THE INTERNET
Timothy S. Hall*
INTRODUCTION
The Internet provides the pharmaceutical industry with an unparalleled
opportunity to provide virtually unlimited amounts of information
about its products to consumers and potential consumers of those
products. Informed consumers, in turn, potentially could become safer,
more cost-effective, more rational users of prescription drugs.
Information sent directly to the consumer could improve patient
satisfaction, compliance with treatment regimens and, ultimately,
health care outcomes. However, to date, despite spending staggering
amounts of money on direct-to-consumer ("DTC") advertising to reach
consumers and potential consumers of its product,' the industry has
failed to take full advantage of this opportunity. First, it has failed to
prevent the marketplace from being invaded by suboptimal purveyors
of prescription drugs.2 As a result, the dominant perception of Internet
.Assistant Professor of Law, Louis D. Brandeis School of Law at the University of
Louisville. Thanks to the Health Law Institute at DePaul for inviting me to contribute this
article and to revisit an issue of longstanding interest, and to my research assistants Chris
Curran and Jason Lacy for their timely and thorough research assistance.
1Adwatch: Featured Issue: Direct-to-Consumer Prescription Drug Advertising, at
http://www.kaisemetwork.org/adwatch (according to one estimate, the drug industry spent $2.5
billion on DTC advertisements for prescription drugs in 2000, up 35% from the previous year).
2For a full discussion of the phenomenon of Internet drug sales, see John Michael Ward,
Online Pharmaceutical Regulation: An Avenue to a Safer World, 24 J. LEGAL MED. 77 (2003);
Charlotte Spears, Consumer Protection: Online Sale of Prescription Drugs to Minors Not
Unconscionable, 30 J. L. MED. ETHICS 315 (2002); Ivette P. Gomez, Note, Beyond the
Neighborhood Drugstore: U.S. Regulation of Online Prescription Drug Sales by Foreign
Businesses, 28 RUTGERS COMPUTER & TECH. L.J. 431 (2002); Mark Sweet, Policing Online
Pharmacies: Bioterrorism Meets the War on Drugs, 2001 DUKE L. & TECH. REv. 41 (2001);
Kristin Yoo, Comment, Self-Prescribing Medication: Regulating Prescription Drug Sales on
the Internet, 20 J. MARSHALL J. COMPUTER & INFO. L. 57 (2001); Nicole A Rothstein,
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drug information is that of the "snake-oil salespeople of the information
age. ' 3  Second, the industry has failed to assure that its own
advertisements provide adequate information to the consumer to
enhance the treatment process. Poorly designed, inadequately
informational or (at worst) misleading advertisement contributes
nothing to the health care decision-making process, and in fact, given
the dangerous nature of prescription drugs, has the potential to do
considerable harm. Commentators, 4 consumer advocates, legislators 5
and the World Health Organization 6 have expressed concern at the
proliferation of Internet promotion of prescription drugs.
The first part of this Article will describe the current regulatory
system for direct-to-consumer advertising of prescription drugs. This
system was developed before the advent of Internet advertising, and has
been slightly re-interpreted, but not wholly reformed, to take account of
increased industry use of Internet and other mass media to
communicate directly with consumers. The second part will describe
the current state of the pharmaceutical industry's Internet-based
marketing efforts. Part three will explore the potential impact of these
marketing efforts on the physician-patient relationship, emphasizing
both the desirable and undesirable effects of Internet DTC advertising.
Comment, Protecting Privacy and Enabling Pharmaceutical Sales on the Internet: A
Comparative Analysis of the United States and Canada, 53 FED. COMM. L.J. 343 (2001); David
B. Brushwood, Responsive Regulation of Internet Pharmacy Practice, 10 ANNALS HEALTH L.
75 (2001); Sara E. Zeman, Regulation of Online Pharmacies: A Case for Cooperative
Federalism, 10 ANNALS HEALTH L. 105 (2001); Ty Clevenger, Internet Pharmacies:
Cyberspace v. the Regulatory State, 15 J.L. & HEALTH 165 (2000); Sean P. Haney, Note,
Pharmaceutical Dispensing in the "Wild West": Advancing Health Care and Protecting
Consumers Through the Regulation of Online Pharmacies, 42 WM. & MARY L. REV. 575
(2000); Amy J. Oliver, Internet Pharmacies: Regulation of a Growing Industry, 28 J.L. MED. &
ETHICS 98 (2000).3Rothstein, supra note 2, at 347.4See, e.g., Ellen 't Hoen, Direct-to-consumer advertising: For better profits or for better
health? 55 AM J. HEALTH SYST. PHARM. 594, 596 (1998) ("[T]he U.S. model of drug
advertising to consumers presents a risk that the pharmacist will end up as a mere extension of
the DTC advertisement").5Concerns about the DTC advertising of prescription drugs have led legislators to try to
discourage drug companies from such activity. In 2001, the Vermont General Assembly passed
a resolution asking Congress to declare a moratorium on DTC advertising. H.R.J. RES. 60 (Vt.
2001). In 2001, bills were introduced in Congress and in California's state legislature that
would have disallowed a deduction from a drug company's income for state tax purposes for
any amount spent to advertise a prescription drug. H.R. NO. 2352, 107th Cong. (2001); S. NO
1099, 2001-02, Reg. Sess. (Cal. 2001). Although the proposed federal bill was targeted at DTC
advertisements, the proposed California bill made no distinction between DTC promotion and
traditional promotion to physicians. Neither bill was enacted.
6press Release, World Health Organization, The World Health Assembly Adopts a
Resolution on the Sale of Medical Products Through the Internet (May 12, 1997),
http://www.who.ch//.
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Finally, we will conclude with suggestions for reform of the regulation
of Internet DTC advertising, and will propose that regulation of Internet
DTC advertising explicitly consider the impact of such promotion on
the physician-patient relationship.
A SHORT HISTORY OF THE REGULATION OF DTC
ADVERTISING
FDA Jurisdiction over DTC Advertising
The Food and Drug Administration enjoys authority over the regulation
of prescription drugs under the Federal Food, Drug and Cosmetics Act
(FDCA).7 Misleading or otherwise inappropriate advertising causes a
drug to be considered a misbranded drug,8 potentially subjecting the
offending manufacturer to criminal and civil liability under the FDCA. 9
Although the FTC also has authority to regulate the advertising of drug
products, 10 the FDA and FTC have entered into a letter of agreement"
with the goal of avoiding unnecessary regulatory overlap between the
agencies. Pursuant to this agreement, the FTC has authority to
regulate all drug advertising except advertising for prescription drugs,
which is regulated by the FDA. 3
When the FDA first regulated prescription drug advertising, such
advertising was solely directed at physicians and other health care
professionals. 14  Drugs were marketed through advertisements in
medical journals and other publications designed to reach the health
care industry; through other promotional materials distributed directly
to physicians and other health care professionals; and through use of
pharmaceutical industry representatives who made visits to physicians'
offices to educate health care workers about and promote the use of
their employers' products. 15  The FDA regulations were designed to
'21 U.S.C.A. § 301 (West 2003).
821 C.F.R. § 202.1(k) (2003).
'21 U.S.C.A. §§ 331(a), 333 (West 2003).
1015 U.S.C. §§ 52-55 (2003). For a discussion of interagency cooperation between FDA
and FTC, see Paul E. Kalb et. al., Direct-to-Consumer Marketing: The FDA is Not Alone, 58
FOOD & DRUG L.J. 25 (2003).
".01 FTC Act §§ 12-16, 15 U.S.C. §§ 52-56 (2001) [hereinafter Letter of
Understanding].
121d.
13!d. Although advertisements of over-the-counter drugs, dietary supplements, and other
products raise interesting and important legal issues, this Article will confine its discussion to
the advertisement of prescription drugs.
14 See Perez v. Wyeth Laboratories, 734 A.2d 1245, 1247 (N.J. 1999).
15AII of these promotional activities continue to this day, although the budget for them
has not increased at the same rate as the budget for DTC promotions in recent years.
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ensure that physicians were provided with adequate information to
competently prescribe the product, and focused on disclosure to the
physician of known contraindications, risks and side effects of the
product being promoted. 16 Thus, all print advertisements are required
to include a "brief summary" of the indications, contraindications and
side effects of the drug in question.' 7  This "brief summary" is
ordinarily the same information that is provided in the Physician's
Desk Reference, is a subset of the required labeling of the drug, and is
technical in nature.' 8  "Reminder" advertisements, which merely
consist of the name of the drug, but do not discuss dosage information
or indications for the drug's use, need not contain the brief summary. 19
"Help-seeking" ads, which do not state the name of a drug, but merely
describe an illness or symptoms and advise the viewer or reader to "see
your doctor" are not considered drug advertisements, and so are not
regulated by the FDA.2 °
Despite this existing exercise of its authority to regulate
advertisements of prescription drugs, DTC advertisements seemed to
catch the FDA off guard. When the first DTC ads began to appear in
the 1980s, 21 the response of the FDA was to request a voluntary
161t is not at all clear that directing advertising material at physicians in fact
accomplishes the goals of educating physicians and improving the quality of practice.
Empirical research has shown that the more promotional material a physician is exposed to, the
less rational is her prescribing practice. See Joel Lexchin, Pharmaceutical Promotion in
Canada: Convince Them or Confuse Them, 17 INT'L J; HEALTH SERV. 77, 86 (1987) ("The
more doctors rely on commercial services for their information about drugs, the less rational
they are as prescribers.").
17See David W. Opderbeck, How Should FDA Regulate Prescription Drug Promotion on
the Internet?, 53 FOOD DRUG L.J. 47, 55 (1998)
181d. ("Practically speaking, the brief summary is essentially the same as the prescribing
information required under the labeling regulations.").
19While a reminder ad might make sense directed to prescribing physicians by keeping
the product in their minds, the same technique applied to consumer advertising, while
successful in creating interest in and awareness of the drug brand, also created substantial
confusion. Kelly Reeves, Direct-to-Consumer Broadcast Advertising: Empowering the
Consumer or Manipulating a Vulnerable Population, 53 FOOD DRUG L.J. 661 (1998)
(describing the interest in Claritin generated by reminder ads, which caused patients to ask
physicians about the drug with no idea what the drug's indications or benefits were).20Div. DRUG MKTG., ADVER. & COMM., U.S. FOOD & DRUG ADMIN., STATEMENT OF
NANCY M. OSTROVE, Ph.D. (2001) [hereinafter Statement of N. Ostrove]. Although the FDA
does not regulate help-seeking ads, it has issued warning letters to drug companies based on
these ads. Id. Warnings based on help-seeking ads generally allege that the ad states the name
of a specific drug, or implies the identity of the drug being promoted. Id. Since help-seeking
ads cannot mention the name of the drug, they are most often used for drugs which are the only
treatment for a particular condition, or which are the market leader for treatment of that
condition, and thus can expect to gain a large share of the demand created by the ad.2
'The advertisements which caused the most controversy, and which are the subject of
this Article, are the so-called "product claim" advertisements, which both name a specific drug
Vol. 7. 1:1
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moratorium on DTC advertisements from the pharmaceutical industry
while the FDA studied the appropriate approach to such
advertisements.22 This moratorium lasted from 1983 until 1985.23
After its initial study of the merits and detriments of DTC
advertising, the FDA reversed its initial moratorium on such
advertising. 24  The FDA stated at that time that it considered that no
new regulation was required to specifically address direct to consumer
advertising; rather, that existing regulations were sufficient to protect
the health and safety of consumers. This decision had the effect of
allowing advertisements for prescription drugs to be placed in media
directly marketed to consumers of prescription drugs rather than to
health care professionals, but required that the advertisement contain all
of the warning and side effect information presented to prescribing
physicians in the "brief summary., 26 After the FDA's decision to lift
the moratorium, print advertisements for prescription drugs
flourished.27 Due to the disclosure requirements, however, broadcast
and make claims about the effectiveness of that drug. See, e.g., 50 Fed. Reg. 36677 (voluntary
moratorium on DTC ads only to "apply to all product-specific advertising that promoted a drug
for its intended uses.") Pharmaceutical companies have also engaged in so-called "reminder"
advertisements, which mention the name of the drug but not its intended therapeutic use, and
"help-seeking" advertisements, which invite sufferers from a particular ailment to "see your
doctor" for information about treatments. See Statement of N. Ostrove, supra note 20. The
scholarly literature on DTC advertisement has focused almost exclusively on product-claim
advertisement.
22Direct-to-Consumer Advertising of Prescription Drugs: Withdrawal of Moratorium, 50
Fed. Reg. 36677 (Sept. 9, 1985) (describing speech by FDA Commissioner and Policy
Statement of FDA requesting moratorium). At least one commentator has criticized the practice
of the FDA in requesting a voluntary industry moratorium. Writing in response to FDA's
Request for Comment of First Amendment Issues (Docket No. 02N-0209), Patrick Maines and
Richard T. Kaplar of The Media Institute criticize the FDA's use of "extra-regulatory means
such as 'draft' policy papers, 'requests' to drug companies, jawboning, and other techniques
that yielded industry compliance without bothering with the Administrative Procedure Act or
statutory provisions for rulemaking." PATRICK MAINES & RICHARD T. KAPLAR, MEDIA INST.,
COMMENTS OF THE MEDIA INST. (2002), available at http://www.fda.gov ("Drug companies ...
were forced to relinquish their constitutional rights rather than jeopardize their business
interests by challenging FDA's practices."). Whether or not the drug industry found the FDA's
request for a moratorium coercive, there is little doubt that they substantially complied with the
moratorium. Statement of N. Ostrove, supra note 19 (stating that industry complied with the
moratorium).
2350 Fed. Reg. 36677 (withdrawing moratorium and allowing advertisement of
prescription drugs to consumers based on existing regulations).24Id.
25Id"
2621 U.S.C.A. § 352(n) (West Supp. 2003).
27Mae Joanne Rosok, Comment, Direct-to-Consumer Advertising of Prescription Drugs:
After a Decade of Speculation, Courts Consider Another Exception to the Learned
Intermediary Rule, 24 SEATTLE U. L. REv. 629, 649 (2000) (describing "stead[y] increase" in
direct-to-consumer spending after the withdrawal of the moratorium).
2003]
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product claim advertisements were still discouraged due to the
difficulty in providing the brief summary within the confines of abroadcast ad.2
In 1997, the FDA revisited the issue of broadcast prescription drug
advertising to consumers. The FDA issued a draft industry guidance
re-interpreting the regulations governing prescription drug advertising
in broadcast media,29 which guidance was issued in final form in
1999.30 This re-interpretation had the effect of relaxing prior
restrictions on broadcast DTC advertisements. 31 Under the Guidance,
drug manufacturers are permitted to air product claim advertisements,
so long as they also provide a statement in the advertisement itself of
the major risks associated with the use of the drug, and the
advertisement exhibits "fair balance" between the product claims and
the risk disclosures.32 Significantly, a broadcast advertisement need no
longer carry the full text of the "brief summary" of information
designed for the use of prescribing physicians. 33 In order to satisfy the
requirement of the regulations that adequate provision be made for
viewers of the ad to obtain the full labeling information for the drug,
34
FDA articulated four methods of providing that information which
28Although existing regulations provide that, as an alternative to providing the brief
summary within the ad itself, advertisers may make "adequate provision" for viewers of the ad
to obtain the labeling information for the drug, uncertainty about what would constitute
"adequate provision" discouraged widespread use of broadcast product claim ads until 1997.
Lars Noah, Advertising Prescription Drugs to Consumers: Assessing the Regulatory and
Liability Issues, 32 GA. L. REv. 141, 148 (1997) ("the brief summary requirement makes non-
print advertising virtually impossible ... and ... substantially increases the cost of print
advertising.").29Broadcast media are defined as radio, television and telephonic communications. The
Internet is not defined as a broadcast medium, and there is no reference to advertising over the
Internet at all in the Guidance, only reference to the Internet as a conduit for the risk
information for a drug advertised over broadcast media. CTR. FOR DRUG EVAL. & RES.,
Guidance for Industry: Consumer-Directed Broadcast Advertisements (U.S. FOOD & DRUG
ADMIN. 1999) available at http://www.fda.gov/cder/guidance/index.htm [hereinafter Broadcast
Guidance].301d.
31See Hoen, supra note 4. The Broadcast Guidance does not apply to print DTC
advertising, in which the "brief summary" must still be included. Broadcast Guidance, supra
note 25. In 2001, the FDA issued a draft Guidance which would allow drug manufacturers to
use FDA-approved patient labeling, rather than the more complex physician labeling, as their
"brief summary," provided that such approved patient labeling carries a complete statement of
the drug's "most serious and most common risks." CTR. FOR DRUG EVAL. & RES., Guidance for
Industry, Using FDA-Approved Patient Labeling in Consumer-Directed Print Advertisements,
(Draft Guidance) (U.S. FOOD & DRUG ADMIN. 2001) available at
http://www.fda.gov/cder/guidance/index.htm.32Broadcast Guidance, supra note 25, at 2.
3 3 d. at 1.
341d. at 2.
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would be deemed to constitute adequate provision.35  First, the
manufacturer could establish a toll-free phone number which
consumers could call to either request a copy of the information or to
have it read to them over the phone.36 Second, the manufacturer could
establish a website to provide the labeling information. 37  Third, the
manufacturer could indicate to viewers that they could obtain further
information about the drug from their doctor or pharmacist.3" Fourth,
the manufacturer must provide a means for consumers without access
to "sophisticated technology" to obtain the information. 39  The
Guidance indicates that a manufacturer could provide brochures
containing the labeling in sufficient locations (such as grocery stores
and pharmacies) that the intended audience of the ad could obtain it
"without traveling beyond their normal range of activities. ' '4  In
making this provision, however, the manufacturer must be careful to
consider the intended dissemination of the advertisement, and
disseminate the labeling materials comparably.
41
Interestingly, the Guidance explicitly treats telehone advertising
differently than advertising over television or radio. The Guidance
states that "telephone advertisements are different from advertisements
broadcast through television or radio. By participating in the telephone
communication, the consumer has already indicated his or her
willingness to discuss the topic or receive additional information.
Consequently, adequate provision... may be achieved with fewer of
the components... ,,43 This recognition that a motivated consumer may
be expected to take more effort in locating warning information about
the drug should be taken into account in devising adequate regulations
for Internet advertisements.
Despite having no regulations specifically addressing Internet
promotion of prescription drugs, 44 the FDA is actively enforcing its
'Id. at 2-3.36Id. at 2.
17Although existing regulations do not expressly regulate Internet advertising, they do
provide that the Internet can be used to partially satisfy the requirements for adequate provision
for access to the labeling information. See Broadcast Guidance, supra note 25, at 3.
38Id. at 3.
39Broadcast Guidance, supra note 25, at 2-3.40 d. at 3.41See id.
421d.
43Id. at 3-4. The guidance indicates that telephone ads could satisfy adequate provision
through offering to mail or read the labeling to the consumer, as well as telling the consumer to
contact his doctor or pharmacist for more information. Broadcast Guidance, supra note 25, at 4.
44James D. Arden, Unguided Missives: The FDA and Prescription Drug Promotion in
Cyberspace, 5 FOOD DRUG L. INST. (2001) available at http://www.fdli.org.
2003]
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existing regulations in cyberspace.45  Issues raised by FDA
enforcement letters to drug companies regarding their online
advertising include: promotion of unapproved uses for a drug;
advertisements lacking fair balance; outdated material remaining on a
promotional website; and misleading claims in advertising.46
FTC Jurisdiction over DTC Advertising
FTC jurisdiction over direct to consumer prescription drug advertising
is limited by the letter of agreement between the FDA and FTC.47 This
letter gives the FDA jurisdiction over the truth or falsity of
advertisements for prescription drugs, whether aimed at health care
professionals or the public.48 However, the FTC plays a large role in
the regulation of advertisement of drugs generally. Advertisements of
over-the-counter drugs are regulated by the FTC, 49 although the FDA
still retains jurisdiction to the extent that materials disseminated by the
drug manufacturer are deemed to be labeling. 50 Many of the criticisms
of drug advertising discussed in this Article are equally appropriately
leveled at manufacturers and resellers of OTC drugs.
Although the FTC has ceded jurisdiction over advertising of
prescription drugs to the FDA, the FTC has apparently thought more
about specific issues raised by Internet advertising than has the FDA.
In 2000, the FTC produced a publication entitled "Dot Coin
Disclosures" as a guide for businesses advertising on the Internet. 51
While this document is not directly addressed to issues related to
pharmaceuticals, it raises several interesting points about regulation of
Internet advertising in general, which will be relevant to FDA
regulation of Internet prescription drug advertising. 2
First, the FTC reminds us that "fraud and deception are unlawful
no matter what the medium., 53 This reminds us that, while the Internet
may have been trumpeted as a "new economy" and a revolutionary
development, we must be careful not to overemphasize the uniqueness
of the Internet.54 Internet promotion is, after all, fundamentally still
45Kalb et al., supra note 10.4 6Arden, supra note 44.47See Letter of Understanding, supra notes 11-13.481d.
49
,d.
501d.
51See Fed. Trade Commission, Facts for Businesses: Dot Com Disclosures (2000),
www.ftc.gov/bcp/conline/pubs/buspubs/dotcom/index.html [hereinafter Dot Corn Disclosures].
52 Id.
53Id. at 1.54See, e.g., Noah, supra note 24.
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promotion, and the target audience of the Internet deserves the same
protections as the target audiences of traditional print and broadcast
advertisements, taking into account the diversity of the new media.
Second, the FTC gives some specific guidance on how to
incorporate relevant disclosures into Internet promotions.55 The FTC
suggests, among other techniques, the following relevant points:
1. Disclosures should be placed on the same screen as the
product claims. 6
2. Relevant material should not be hidden at the bottom of
pages without references in the viewable portion to tell
visitors to scroll down.57
3. Hyperlinks to material presented on separate pages
should be obvious, adequately labeled, placed near relevant
information, and consistent throughout the site. 8
4. Make sure that warning or risk information is
prominently displayed in relation to other components of the
site.59
55Dot Com Disclosures, supra note 44.
56d. This is probably not practical for the full package labeling. No one would expect the
full package labeling to appear on the same web page as the main ad, and the FTC guidelines
themselves recognize that "hyperlinked disclosures may be particularly useful if the disclosure
is lengthy..." Id. However, a further issue is whether the "fair balance" requirement applies to
the web site as a whole, or to each page in the site. The FTC guidance seems to suggest the
latter approach. FTC notes that "consumers don't read an entire web site, just as they don't read
every word on a printed page." Id. Thus, it is not sufficient to "[m]ak[e] the disclosure available
somewhere in the ad so that consumers who are looking for the information might find it..." Id.
The FDA should adopt a similar approach to evaluation of promotional web sites.
57This is clearly relevant to drug home pages, as most of them provide links to the
adequate provision material only through small type links at the bottom of the page. In
addition, if risk information is presented on the home page, it is invariably placed in plain text
at the bottom of the page. One thing that site designers must take account of in this context is
that there is no fixed size for computer screens, and that the amount of text displayable on a
640x480 screen is less than that displayable on a 1200X1600 screen. The FTC advises
advertisers to "be concerned about whether a required disclosure will appear [on a particular
user's computer.]" Dot Corn Disclosures, supra note 44, at § III.C. 1.c.58The FTC makes the point that with available technologies, web designers can monitor
the rates at which visitors to the site actually make use of hyperlinks to relevant risk
information and warnings, and can use these data to modify the site design as needed to ensure
that visitors are receiving fairly balanced information on the product. Dot Corn Disclosures,
supra note 44.
59Id. This includes several specific points: provision of risk information in the same
format as the product claims (i.e., audio risk information if the product claim is made aurally);
placement of disclosures in noticeable places on the page, and making them similar in look and
feel to the product claim material; ensuring that the promotional material does not distract from
the disclosure; and using consumer-friendly language in the disclosure. Id. Many drug
promotion websites are marginal on many of these aspects of disclosure.
2003]
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Tort as Regulation of DTC Advertising
In addition to FDA and FTC rulemaking, tort law can also be
considered a regulatory device. Among the aims of tort law in this
context are the deterrence of improper promotional devices and the
allocation of harms to the party causing those harms. 61 To the extent
that tort law seeks to impose the costs of both defective design and
defective marketing on the entity responsible for placing products and
marketing into the stream of commerce, 62 it is regulatory in purpose
and effect. The relevant issue, then, is the effect of tort law on the
market for DTC advertising of prescription drugs.
The Learned Intermediary Rule
Modem American products liability law provides for strict liability for
harms caused by products which are introduced into the marketplace
by, or pass through the hands of, a particular manufacturer or seller.
63
Liability may be premised on the defective design of the product in
question, or on the manufacturer's or seller's failure to warn the
customer of non-obvious harms arising from the use of the product.
64
Ordinarily, a warning must be communicated to the end user of the
product in order to be legally sufficient.65  However, in cases of
prescription drugs, this rule has been substantially different. Under the
Restatement (Second) of Torts, prescription drugs could not be
considered defective in design merely by reason of injury resulting
from the product.66 The now-famous Comment k to section 402A of
the Second Restatement provided for an exception to strict liability for
"unavoidably dangerous" products (a category which includes
prescription drugs) as long as a warning about their dangerousness has
6
°Michael D. Green, Safety as an Element of Pharmaceutical Quality: The Respective
Roles c/ Regulation and Tort Law, 42 ST. Louis U. L.J. 163 (1998).
'See, e.g., Peter L. Kahn, Regulation and Simple Arithmetic: Shifting the Perspective on
Tort Reform, 72 N.C. L. REv. 1129, 1161 (speaking of a "coincidence of concerns between tort
and regulation.")62RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 1 (1998).631d. ("One engaged in the business of selling or otherwise distributing products who
sells or distributes a defective product is subject to liability for harm to persons or property
caused by the defect.").
64RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 (1988). Claims involving
harm caused by prescription drugs generally do not claim that the drug was improperly made,
although such litigation is not unknown. FRANK WOODSIDE, DRUG PRODUCT LIABILITY § 14.01.651Id § 2, cmt. i.66See RESTATEMENT (SECOND) OF TORTS § 402A cmt. k. (1965). See also James
Henderson and Aaron Twerski, Drug Designs are Different, 111 YALE L. J. 151 (2001); James
A. Henderson, Prescription Drug Liability Under the Proposed Restatement (Third) of Torts: A
Reporter's Perspective, 48 RUTGERS L. REv. 471 (1996).
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been given.67  The Restatement (Third) of Torts - Products Liability
continues this basic rule.
68
Although a legally adequate warning is ordinarily delivered to the
ultimate user of the product, courts have uniformly applied the Learned
Intermediary Rule ("LI Rule") to insulate drug manufacturers from
liability for injuries caused by their products, as long as the drug
manufacturer has taken adequate steps to warn prescribing physicians
of known dangers of the drug.69  However, the LI Rule is not an
absolute immunity from liability for prescription drug manufacturers.
Courts have held that the Learned Intermediary Rule does not
apply, and thus that drug manufacturers owe a duty to warn the
individual patient directly, in situations involving mass
immunizations.7y In these cases, courts reason, the immunization is not
delivered in the context of an existing doctor-patient relationship; thus,
there is no effective "intermediary" between the patient and the drug
manufacturer. 71  Because the patient cannot expect a full and fair
disclosure of the risks and benefits of the treatment in the context of its
delivery, courts have been willing to impose that duty on the drug
manufacturer.72  Note that this doctrine does not apply to
immunizations carried out in the context of an existing physician-
67RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (1965).
68The Third Restatement provides that a manufacturer or seller of a prescription drug is
liable for harm caused by "defective" drugs. RESTATEMENT (THIRD) OF TORTS: PRODUCTS
LIABILITY § 6 (1998). "Defect" is defined, inter alia, as a failure to provide appropriate and
adequate warnings and instructions for use of the product. Id. at § 6(d). In 1997, Professor Lars
Noah suggested that, in light of the Restatement (3d) of Torts' suggestion that the learned
intermediary doctrine may not apply where a drug manufacturer advertises directly to
consumers, "pharmaceutical manufacturers may choose to discontinue most promotions
directed to persons other than medical professionals." Noah, supra note 24. Clearly, this has not
happened, and industry spending on direct-to-consumer advertising has continued to rise
unabated.69WOODSIDE, supra note 49, at § 14.02[1][b][ii]. Some courts have recognized an
"overpromotion" theory to avoid the LI Rule's exemption from tort liability. See, e.g., Stevens
v. Parke, Davis & Co., 507 P.2d 653 (1973). Where a drug manufacturer delivers a technically
accurate warning to prescribing physicians in the context of a promotional, highly positive
communication, courts have held that the promotional nature of the communication outweighed
and diluted the warning, and that the warning was thus insufficient to trigger the protections of
the LI Rule. Id. at 661 ("an adequate warning to the profession mat be eroded or even nullified
by overpromotion of the drug through a vigorous sales program which may have the effect of
persuading the prescribing doctor to disregard the warnings given.").
7
°Petty v. U.S., 740 F.2d 1428, 1440 (8th Cir. 1984); See also Allison v. Merck & Co.,
878 P.2d 948 (Nev. 1994).7 1Petty, 740 F.2d at 1440 ("[I1n a mass-immunization context, where there is no learned
intermediary, the duty extends to the ultimate recipient...").72/d.
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patient relationship, where the considerations of the LI Rule would
naturally apply with full force.
73
In addition to mass immunizations, an exception has been carved
out of the LI Rule for oral contraceptives.74 Like the immunization
rule, this exception rests at least in part on the absence of an effective
physician-patient relationship.75 Unlike the immunization rule, it does
not depend for its effectiveness on whether a physician is involved in
the administration of the drug.76
The birth control exception was created out of courts' recognition
of the unusual nature of this product and the manner in which it is
prescribed and used. Birth control drugs, while prescription
pharmaceutical products, are ordinarily not used for the treatment of a
specific illness, but out of a desire to prevent pregnancy.77 The drug is
thus more akin to a lifestyle choice than a medical choice.78 Because of
this, the decision to use the drug is much more in the hands of the
patient than of the physician; that is, the use of birth control drugs is
ordinarily not an exercise of medical judgment.79 In addition to this,
the product is ordinarily prescribed once per year, and the patient does
not ordinarily return to the physician's office for further consultation
more frequently than annually.80 Thus, some courts have held that the
LI Rule does not apply in this context.
81
Finally, the FDA has mandated certain information to be provided
directly to patients taking certain prescription drugs. 82 For this reason,
some courts hold that the LI Rule is inapplicable, and that warnings
about the product must be directed to the patient, based on the
regulatory decision to mandate that information be provided to the
73Niemiera v. Schneider, 555 A.2d 1112 (N.J. 1989); See also Conafay v. Wyeth
Laboratories, 793 F.2d 350 (D.C. Cir. 1986).74See generally Stephens v. G.D. Searle & Co., 602 F. Supp. 379 (E.D. Mich. 1985);
Odgers v. Ortho Pharm. Corp., 609 F. Supp. 867 (E.D. Mich. 1985); Lukaszewicz v. Ortho
Pharm. Corp., 510 F. Supp. 961 (E.D. Wis. 1981).75See Stephens v. G.D. Searle & Co., 602 F. Supp. 379 (E.D. Mich. 1985); Lukaszewicz
v. Ortho Pharm. Corp., 510 F. Supp. 961 (E.D. Wis. 1981).76See MacDonald v. Ortho Pharm., 475 N.E.2d 65, 66-67 (Mass. 1985) (plaintiffs
prescription obtained from her personal gynecologist).
77 d. at 69 n. 10.
78See id.79Id"
80See id. at 69 n. 11.
81But see Cobb v. Syntex Labs Inc., 444 So.2d 203 (La. Ct. App. 1983).
82See 21 C.F.R. §201.305; 310.515. Included in this list are oral contraceptives, so this
rationale constitutes another justification for the contraceptive exception as well.
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patient. 83 States are split on the question of whether compliance with
the FDA mandate constitutes per se adequacy of warnings for the
purpose of tort liability.
84
Critics of the Learned Intermediary Rule
The Learned Intermediary Rule has been the subject of intense
scholarly criticism since the advent of direct-to-consumer advertising.
In addition, since the advent of DTC advertising, the relevant
provisions of the Restatement of Torts have been rewritten in a manner
which arguably suvorts a DTC advertising exception to the Learned
Intermediary Rule. This section will explore these objections to the
rule, and will suggest that DTC advertising, particularly advertising on
the Internet, justifies abrogation of the LI Rule in limited
circumstances.
In the early 1990s, scholarly commentary critical of the LI Rule as
applied to cases involving DTC advertising began to appear in law
journals. 86  Despite the scholarly criticism of the Rule in the DTC
advertisement context, only one court to date has adopted the reasoning
of the Rule's critics.
In Perez v. Wyeth Laboratories, the Supreme Court of New Jersey
recognized an exception to the LI Rule where the drug manufacturer
has engaged in extensive DTC advertising.87 The plaintiffs in Perez
were individuals who had used the long-term implantable contraceptive
83See, e.g., Edwards v. Basel Pharm., 116 F.3d 1341 (10th Cir., 1997); McKee v. Moore,
648 P.2d 21 (Okla. 1982); Lukaszewicz v. Ortho Pharm. Corp., 510 F. Supp. 961 (E.D. Wis.
1981). 84See generally RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY §6(c-d); comment
b to §6 (takes the position that compliance with FDA requirements does not constitute per se
adequacy of the warning as a matter of tort law).
1 Restatement (Third) of Torts: Products Liability §6, reads in relevant part:
(d) A prescription drug or medical device is not reasonable safe due to inadequate
warnings or instructions if reasonable instructions or warnings regarding foreseeable risks of
harm are not provided to:
(1) prescribing and other health-care providers who are in a position to reduce the
risks of harm in accordance with the instructions or warnings; or
(2) the patient when the manufacturer knows or has reason to know that health-
care providers will not be in a position to reduce the risks of harm in accordance with the
instructions or warnings. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 686See Timothy S. Hall, Bypassing the Learned Intermediary: Potential Liability for
Failure to Warn in Direct-to-Consumer Prescription Drug Advertising, 2 CORNELL J.L. & PUB.
POL'Y 499 (1992); See also Patrick Cohoon, Comment, An Answer to the Question Why the
Time Has Come to Abrogate the Learned Intermediate Rule in The Case of Direct-to-Consumer
Advertising of Prescription Drugs, 42 S. TEX. L. REv. 1333 (2001); See also April L. Foreman,
Web of Manipulation, The Learned Intermediary Doctrine and Direct-to-Consumer Advertising
on the World Wide Web, 35 J. MARSHALL L. REv. 97 (2001).87 Perez v. Wyeth Lab., 734 A.2d 1245 (N.J. 1999)
2003]
DEPAUL JOURNAL OF HEALTH CARE LAW
Norplant, and who alleged that they were injured by side effects of
the medication, as well as by pain and scarring caused during the
removal of the device. 89 Although many physicians had published in
medical j0oumals reports of difficulties with the removal of Norplant
capsules, 0 no mention of this fact, or of other known side effect of the
medication,91 was made in the extensive DTC advertising campaign
undertaken by Wyeth to promote Norplant.
92
The Perez court acknowledged that in product liability cases
involving prescription drugs, the LI Rule is still the law of the State of
New Jersey. 93 However, the court reasoned that the Rule is justified by
certain assumptions about the marketing and sale of prescription drugs,
which assumptions are not necessarily true in cases where prescription
drugs have been marketed directly to the public.94 The court articulated
three rationales for abrogation of the LI Rule in cases involving
extensive DTC advertising:
1. The shift to patient-centered ethics, centered on the
doctrine of informed consent, the decline of paternalism, and
the patient's right to participate in health care decision
making;9
5
2. The effects of managed care on the doctor-patient
relationship, which decreases the amount of time a doctor
has to deliver an adequate warning to the patient;
96
3. The development of communication from the drug
manufacturers to patients and potential patients though mass
media.
97
88Although the court acknowledged that, because of the nature of the Norplant product
(the drug comes in capsules which are inserted under the skin of the patient and release the
contraceptive drug continually into the bloodstream), the product might be thought of as a
medical device instead of a drug, it analyzed the case as though Norplant were a drug, and this
Article will also so assume. Id. at 1251.89Although Norplant is a long-acting delivery system for contraceptive drugs, the
capsules must be removed and replaced at periodic intervals.
90Perez, 734 A.2d at 1248.
91Side effects of Norplant included "weight gain, headaches, dizziness, nausea, diarrhea,
acne, vomiting, fatigue, facial hair growth, numbness in the arms and legs, irregular
menstruation, hair loss, leg cramps, anxiety and nervousness, vision problems, anemia, mood
swings and depression, [and] high blood pressure[.]" Id.921d.
93Perez, 734 A.2d at 1250.
94Id. at 1252-53.
95See id. at 1255 ("The decision to take a drug is 'not exclusively a matter for medical
judgment."') (quoting Theresa Moran Schwartz, Consumer-Directed Prescription Drug
Advertising and the Learned Intermediary Rule, 46 FOOD DRUG CosM. L.J. 829, 831 (1991)).
See also BEAUCHAMP & CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS (5th ed. 2002).961d.
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Although the New Jersey court was willing to recognize an
exception to the LI Rule for DTC promotion of prescription drugs, the
actual contours of the rule are quite limited for potential plaintiffs.98
The court held that compliance with FDA guidelines on DTC
advertising would constitute a rebuttable presumption that the warning
provided to patients was adequate to avoid tort liability.99 In order to
establish liability on the grounds of failure to warn through advertising,
then, a plaintiff must prove either:
1. The drug manufacturer failed to abide by FDA guidelines
for advertising prescription drugs to consumers;' 00 or
2. The advertising material which met the FDA guidelines
was nonetheless legally inadequate for some reason. 1°1
The Persistence of the Learned Intermediary Rule
Despite these criticisms, and the adoption of the criticisms by the
Supreme Court of New Jersey, other courts have been reluctant to
abandon the LI Rule in the face of DTC advertising by drug
manufacturers. 0 2 No other court has adopted the exception articulated
by the New Jersey court in the four years since the Perez case. Further,
scholarly objection to the LI Rule in this context is by no means
unanimous - many learned commentators have opined that the LI Rule
remains the appropriate lens through which to view the relationship
between the drug manufacturer and the consumer of prescription
drugs.
10 3
971d.
98See Perez, 734 A.2d at 1250.
991d. at 1257-59.
100To the extent that critics of the pharmaceutical industry are correct that drug
companies often violate FDA guidelines in their DTC advertisements, however, this standard
may not be an insurmountable bar to liability. Id. at 1259.
l 0lSee id.102See, e.g., In re Norplant Contraceptive Products Liability Litigation, 165 F.3d 374 (5th
Cir. 1999).103See, Charles J. Walsh et al., The Learned Intermediary Doctrine: The Correct
Prescription for Drug Labeling, 48 RUTGERS L. REV. 821 (1996); See also Noah, supra note 24,
at 89; Jack B. Harrison, Some Accurate Information is Better than no Information at All:
Arguments Against an Exception to the Learned Intermediary Doctrine Based on Direct-to-
Consumer Advertising, 78 OR. L. REV. 605 (1999); Richard C. Ausness, Learned
Intermediaries and Sophisticated Users: Encouraging the Use of Intermediaries to Transmit
Product Safety Information, 46 SYRACUSE L. REV. 1185 (1996); Barbara Pope Flannagan,
Comment, Products Liability: The Continued Viability of the Learned Intermediary Rule as it
Applies to Product Warningsfor Prescription Drugs, 20 U. RICH. L. REV. 405 (1986).
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Judicial Review ofAdvertising Content?
In late 2002, a federal judge in California issued an injunction against
GlaxoSmithKine, maker of the prescription antidepresseant Paxil,
ordering the company to cease airing television advertisements which
claimed that Paxil was "non-habit forming." 10 4  This injunction was
granted in response to a motion from plaintiffs' attorneys in a class
action lawsuit alleging, inter. alia, failure to warn plaintiffs of Paxil's
side effects. 1°5  Although the injunction was later denied upon
defendant's motion for reconsideration,10 6 the opinion denying the
motion contains language in dicta indicating that the court possesses
the power to issue such an injunction in appropriate circumstances.
This case drew a brief from the FDA arguing that such an injunction
would create undesirable state-to-state variation in the legal
requirements for prescription drug advertising. 107
DTC ADVERTISING ON THE INTERNET -
WHO, WHY AND HOW?
Direct-to-consumer advertising is rapidly expanding, and companies
are seeking more venues for targeting promotional messages to
potential consumers. 1° 8 Since the Internet is a richly varied medium,
advertising practices on the Internet are similarly diverse. This section
will provide a short synopsis of the major Internet advertising
techniques. Although the Internet blurs the lines between
advertisement and sale, 1°9 this Article will not address issues related to
the sale of prescription drugs over the Internet.'l 0
1°4In re Paxil Litigation, No. CV 01-07937 MRP, 2002 WL 31375497 (C.D. Cal. Oct.
18, 2002).
'See id.
106Id.
107Melody Petersen, Judge Orders Drug Company to Alter Ads, N.Y. TIMES, Aug. 21,
2002.
108See Suzanne Vranica, Patient Channel to Blast Ads at Bedridden, WALL ST. J., Sept.
26, 2002, at BI.
109Through the use of hyperlinking, pharmacies can make it easy for purchasers to move
directly from a website extolling the virtues of a particular drug to ordering that drug. Contrast
this to the ordinary relationship between advertising and purchase, where there is ordinarily a
lengthy delay between viewing a print or broadcast advertisement, seeking an appointment with
one's physician to discuss the proposed treatment, and obtaining a prescription to be filled at a
local pharmacy.
"
0Many if not all Internet pharmacies maintain web sites which may consist of both
promotional materials as well opportunities to purchase drugs. For a discussion of the issues
raised by Internet sales of prescription drugs, see Kristin Yoo, Comment, Self-Prescribing
Medication: Regulating Prescription Drug Sales on the Internet, 20 J. MARSHALL J. COMPUTER
& INFO. L. 57 (2001); Nicole A. Rothstein, Comment, Protecting Privacy and Enabling
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Economics of Internet Advertising
Since the Internet was first opened to commercial traffic in 1991,1" the
growth of "e-commerce" has been dramatic. With total sales of $43.4
billion in 2002, up 25.6% from 2001 sales,112 the Internet accounts for
an increasing percentage of American commerce."1 3  Further, the
audience for Internet advertising is also growing dramatically, and is
encompassing segments of the population attractive to marketers.
Use of the Internet is penetrating into virtually every sector of
American society. Although experts have expressed concern at the
"digital divide" that threatens to create a new categorization of "haves"
and "have-nots,"' 14 recent Census data show gains in Internet
connectivity in households of every ethnic background. 1 5 In 2000, for
the first time, more than half (51%) of American households owned a
computer, and 41.5% of households had Internet access. 16  Overall,
household Internet access grew 58% during the two-year period from
1998-2000.' In addition to those whose homes provide Internet
access, 8.7% of the population reported accessing the Internet solely
from outside the home - from computers at work, at school, or in other
public facilities. 118
Internet access correlates positively with household income,
making Internet users an attractive group for the attention of marketers.
While 41.5% of American households enjoy Internet connection, that
number surges to 77.7% among households with annual incomes of
$75,000 per year or greater.1 9
Pharmaceutical Sales on the Internet: A Comparative Analysis of the United States and
Canada, 53 FED. COMM. L.J. 343 (2001); David Brushwood, Responsive Regulation ofInternet
Pharmacy Practice, 10 ANNALS HEALTH L. 75 (2001); Ty Clevenger, Internet Pharmacies:
Cyberspace Versus the Regulatory State, 15 J.L. & HEALTH 165 (2001); David Mills,
Cybermedicine: The Benefits and Risks of Purchasing Drugs over the Internet, 5 J. TECH. L. &
PUBLIC POL'Y 1 (2000); Rebecca Porter, Internet Pharmacies: Who's Minding the Store?, 36
TRIAL 12 (May 2000).
11 See Opderbeck, supra note 16, at 48.
112Retail sales numbers from U.S. Census data. U.S. CENSUS BUREAU, U.S. DEP'T OF
COMMERCE NEWS (2003), available at http://www.census.gov/mrts/www/current.html.
13 Id. Currently, Internet commerce accounts for approximately 1.5% of all retail sales in
the United States.
... NAT'L TELECOMM. & INFO. ADMIN., Falling Through the Net: Toward Digital
Inclusion (U.S. DEPT. OF COMMERCE Oct. 2000) at http://purl.access.gpo.gov/GPO/LPS6464
[hereinafter Falling Through the Net].
J)SSee id. at xvi.
161d. at 1, Figure I-1.
1 7Id. at 2.
"'Id. at 46.
"
9Falling Through the Net, supra note 104, at 9.
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Drug manufacturers and retailers have found Internet advertising
to be a cost-effective way of communicating with potential patients,
compared to traditional advertising media such as television and
print. According to one analysis, Internet advertising cost the
pharmaceutical industry $54 per drug request resulting from Internet
advertising, substantially less than the $152 per drug request for
television advertising and $318 per request for print advertising. 12 1
Further, unlike print or television ads, which tend to be broadcast to a
wide audience indiscriminately, 122 Internet ads can be targeted at those
Internet users who are likely to be interested in purchasing the drug in
question, as evidenced by either their having visited the promotional
website of the manufacturer, a portal or support website dedicated to
information about a particular disease or treatment, or through analysis
of data collected about that user from the use of "spyware," software
which tracks a specific user's Internet surfing habits and transmits data
about those habits to a centralized database.12 3 Health care advertising
is a natural fit for the Internet, as studies report that a large percentage
of the informational searches on the Internet are seeking health care
related information.1
24
Studies have shown both that advertising raises awareness of
prescription drug brands among consumers, and that Internet
advertising results in specific requests to physicians for advertised
drugs. FDA data, while not disaggregating Internet advertising from
other DTC advertising, show that consumer awareness of DTC
advertising in general is quite high, indicating that the advertisements
are reaching the attention of the public. In surveys conducted in 2002,
81% of respondents reported awareness of DTC advertisements. 125 Of
120Michael Pastore, Drug Companies Fail to Harness Internet's Marketing Potential
(citing Cyber Dialogue (Fulcrum Analytics) at http://www.cyberdialogue.com) at
http://www.cyberatlas.Intemet.com/markets/healthcare/article/0,1323,10101_701591,00.html
(numbers from Cyber Dialogue).
1221d.
122See Vranica, supra note 112 (an example of television advertisements which is
somewhat targeted to the intended audience: aimed at hospital patients).
123See Robert O'Harrow, Jr., Firm Tracking Consumers on the Web for Drug
Companies, WASH. POST, Aug. 15, 2000, at El.
124In 1996, more than 70 million Americans used the Internet to search for health
information. Ross Silverman, Regulating Medical Practice in the Cyber Age: Issues and
Challenges for State Medical Boards, 26 AM. J. L. & MED. 255 (2000).
125Kathryn J. Aikin, Ph.D., Direct-to-Consumer Advertising of Prescription Drugs:
Patient Survey Results, OFF. MED. POL'Y Div. OF DRUG MKTG., ADVER., & COMM. (U.S. FOOD
DRUG ADMIN.), at http://www.fda.gov/cder/ddmac/Presentations/KitHMCC2002out (Oct. 22,
2002).
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these, 16% reported having seen an advertisement on the Internet.' 26
Of those exposed to DTC advertisements, 43% reported that the
advertisement led them to seek more information about the drug
advertised. 127 Of these, 38% reported using the Internet to seek more
information.
128
Models of Internet Advertising
Many drug companies, in addition to maintaining corporate websites
with information about the company and its operations, 129 also maintain
promotional websites dedicated to certain of the company's products.13
0
These promotional websites are often linked off the company's main
site, but to aid Internet users in locating them, often have separate
domain names. 131 The domain names may be the name of the drug
itself,132 or may be descriptive of the drug133 or related to the condition
the drug is intended to treat. 134  Indeed, a company may register
multiple domain names for a drug's website, in order to direct as many
Internet searches as possible to its website. 135
Drug company promotional websites, as is common with Internet
site design, generally consist of a "home page" with multiple linked
pages or sections from that home page. Each page is generally
designed to be easily viewed on the average computer monitor, without
requiring extensive scrolling. A drug promotional website's home page
generally consists of both graphics and text. Often, images apparently
intended to represent successful users of the product 136 are combined
with text describing the benefits of the product. In keeping with the
FDA's requirement that promotional information be balanced between
descriptions of the benefits and descriptions of the risks, some
websites, but not all, include on the home page a list of common side
1261d.
127Id.
128 d. Use of the Internet to seek more information about an advertised drug more than
doubled from 1999 to 2002, with 18% of respondents in 1999 reporting Internet searches,
compared to 38% in 2002. Id.129See, e.g., http://www.pfizer.com (an example of a drug company corporate website).130Product-specific promotional websites have been used since 1994, when Coors
established a web site for its Zima alcoholic beverage brand. Gene Koprowski, A Brief History
ofAdvertising on the Web, FORBES CRITICAL MASS, Fall 1999.
131 See, infra notes 132-135.
132See, e.g., http://www.viagra.com; See also http://www.lipitor.com.
133See, e.g., http://www.purplepill.com (website for Nexium, a heartburn medication).
134See, e.g., http://www.allergyrelief.com.
135See id. (redirecting Internet searchers to http://www.clarinex.com).
136See, e.g., http://www.claritin.com (For example, an allergy medication may show
images of individuals exercising outdoors, apparently unaffected by allergies.).
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effects of the drug.137 Other common elements of drug websites are:
incentive offers to encourage visitors to seek prescriptions for the drug
from their 1hysicians,138 information to help visitors control their
symptoms,' 3 self-diagnostic information to help the visitor decide if
the promoted drug is appropriate;140 and an invitation to submit
personal information to the company.14 1 Virtually all drug websites
include a link to the approved patient package insert for the drug.
However, in stark contrast to the highly polished, animated, attractive
websites they accompany, the package insert files are generally merely
scanned copies of the paper package insert, 142 characterized by small
print, dense text and a lack of graphical or consumer-friendly
content. 143
One major difference between the visitor to a promotional website
and a viewer of a print or broadcast ad is that the visitor to the website
is presumably actively seeking information about the product.
Broadcast and print advertisements in national media attempt to place
information about the product in front of as many individuals as
possible, in the hopes that those individuals for whom the information
is relevant will read or view it. Internet websites, on the other hand, do
not call themselves to the attention of a consumer. 144 Rather, the visitor
to a promotional website must have first found the site. This could be
by simply typing in the name of the product as part of a Uniform
Resource Locator ("URL") address. 145  Alternatively, the individual
seeking information could have found a reference to the drug site on a
137Compare http://www.clarinex.com and http://www.viagra.com (including at the
bottom of the page a text-based description of several possible side effects of the drug) with
http://www.prozac.com (including no risk information on the site's home page). Note,
however, that even the Clarinex and Viagra home pages require at least some users to scroll
down the page in order to access the risk information, while the information presenting the
benefits of the drug is featured prominently at the top of the page.
138See, e.g., http://www.clarinex.com (offering a free 7-day trial of the medication).
139See id. (offering information about pollen counts, weather forecasts and other allergy-
related information through a free membership-based web service).
'°See id.
14'See id. (Personal information is solicited in order for the visitor to receive the
promotional 7-day free trial. Access under "personalized" information on the website).
142See, e.g., http://www.spfiles.com/piclarinex.pdf (the patient package insert from the
Clarinex website).
143Indeed, some online package inserts are virtually unreadable. See
http://www.astrazeneca-us.coml/pi/nexium.pdf (the linked page from the Nexium website,
which opens an unresizable window which, at 100%, is completely unreadable).
144Of course, other Internet advertising techniques, such as mass email or banner or
popup ads on related websites, may resemble print advertising much more closely in this regard
than promotional web sites.
'45Many companies have registered the names of their products as domain names on the
Internet. See, e.g., http://www.claritin.com.
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search engine such as Google, 146 or might have followed a link in a
banner or "pop-up" advertisement from another website. Generally
speaking, however, access to a promotional website requires an intent
on the part of the visitor to find the information contained on that
site. 1
47
Because of the decentralized nature of the Internet, there are many
sites of interest to individuals seeking any particular sort of health
information. Some websites are set up as health "portals," designed to
provide users with a wide range of options, with information about and
links to other sites providing further detail on, a wide variety of health
issues. 148  Other sites are more specific, and may be designed and
maintained by individual patients as online support groups and
information resources for fellow sufferers, by foundations or other
nonprofit institutions designed to provide resources and support for
those with a particular illness, 49 or by for-profit companies seeking to
provide information as an adjunct to their commercial services.
Because of the decentralized nature of the Internet, one of the
earliest problems was how to direct Internet traffic to a particular
website. A prominent method of Internet advertising is the "banner"
ad. These advertisements consist of a small, oblong banner displayed
as part of a website, which, when clicked by a user, direct the user's
browser the destination website of the advertiser. 50  Similar to banner
ads are "pop-up" or "interstitial" ads, which do not display on the same
web page, but open another browser window on top of ("pop-up") or
hidden underneath ("pop-under") the window which the Internet user
has visited. Like banner ads, these advertisements can convey
146Although a search for "viagra" on Google returns 7,380,000 results as of the date of
this writing (June 2, 2003), the first sponsored and non-sponsored links in the list are in fact the
promotional site operated by Pfizer, the manufacturer of the drug. However, prominent
placement on the Google results page is given to another "sponsored link" which is, in fact, the
website of an Internet pharmacy offering Viagra by remote prescription. See, e.g.,
http://www.pillrx.com.
147See, e.g., Dot Com Disclosures, supra note 44 ("Even though consumers have control
over what and how much information they view on Web sites, they may not be looking for - or
expecting to find - disclosures ... Accordingly, disclosures must be communicated
effectively[.]"). Although the fact that the customer sought out the promotional material is
relevant for site design and disclosure purposes, it certainly does not obviate the need to
provide fair balance and make relevant disclosures. See Broadcast Guidance, supra note 25, at
4 (establishing lesser standards for adequate provision in telephone ads compared to broadcast
ads).
148See, e.g. http://www.drkoop.com; See also http://www.webmd.com.
149See, e.g., http://www.lungusa.org (website of the American Lung Association).
150BARBARA K. KAYE & NORMAN J. MEDOFF, JUST A CLICK AWAY: ADVERTISING ON THE
INTERNET 36-37 (2001)
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information as well as provide a link directly to the sponsor's main
website.
Unfortunately, one of the most visible methods of prescription
drug advertising on the Internet is also one of the most ethically and
legally questionable. Unsolicited commercial email, popularly known
as "spam," 15' has experienced a dramatic rise along with the popularity
and utility of the Internet. According to some estimates, spam
constitutes approximately half of all email traffic on the Internet.'
52
Although precise statistics on the amount and frequency of health-
related spam are not available, 153 the prescription drug spam ad has
become part of American pop culture. A recent article in Time
Magazine hailing the fifth anniversary of the sexual-dysfunction drug
Viagra began with the lead "If this article were an email, you would
have deleted it by now," 154 a clear reference to the ubiquity of spam ads
for Viagra.
Spam is one of the cheapest forms of Internet advertising,
155
because it takes advantage of a free-rider phenomenon in American
Internet pricing. Generally, American Internet users pay a flat fee for
Internet access, and do not pay for access on either a time or bandwidth
usage basis. However, ultimately, the social cost of the Internet is
based on the amount of bandwidth used. Thus, Internet service
providers ("ISPs") have an incentive to monitor and control the amount
of bandwidth used by their customers; and in fact, spamming and other
high-bandwidth uses (such as running a website server) are generally
prohibited under most ISPs' standard user contracts. However, not
every ISP enforces these limitations vigorously. Further, the ease of
signing up for Internet access makes it relatively easy for a spammer to
151lntemet legend has it that the term "Spam" is derived from a skit performed by the
comedy troupe Monty Python, which features a Spam-laden restaurant menu. Whether this
legend is accurate or not, it has been enshrined in American case law. See Compuserve v.
Cyber Promotions Inc., 962 F.Supp. 1015, 1018 (S.D. Ohio 1997); See also Hotmail Corp. v.
VanS Money Pie Inc., No. C-98 JW PVT ENE, 1998 WL 388389, at *1 (N.D. Cal. April 16,
1998). While unsolicited email is not as effective at generating response as emailing to
individuals who have requested the information, it does generate up to five percent response
rate. BILL CARMODY, ONLINE PROMOTIONS 249 (Wiley 2001).
152Mark Glassman, Fortifying the In Box as Spammers Lay Siege, N.Y. TIMES, July 31,
2003, at G8.153 0ne source claims that health-related spam constituted 6% of all spain in April 2002.
Jennifer B. Lee, Spain: An Escalating Attack of the Clones, N.Y. TIMES, June 27, 2002, at GI.
154Christine Gorman, Viagra Turns 5: Early Safety Concerns Proved Baseless, and Now
the Competition is Heating up, TIME, January 20, 2003, at 146.
155 0ne estimate places the cost of sending an email solicitation to one million addresses
as between $200 and $2,000. HERSCHEL GORDON LEWIS & JAMIE MURPHY, CYBERTALK THAT
SELLS 18 (Contemporary Books 1998).
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repeatedly switch ISPs as his accounts are blocked for violations of his
service providers' agreement. It is extraordinarily difficult to ban
someone from the Internet, given the decentralization of the net and the
lack of a central governing authority.
Spam is ordinarily not an advertising medium used by drug
manufacturers, but tends to be sponsored by Internet pharmacies
(generally those not operating within the boundaries of professional
standards for Internet pharmacy practice).156
Drug manufacturers, while generally not sending indiscriminate
emailings, do in fact collect lists of email addresses for targeted
marketing. Although these mailings may not be "spam" in the strict
sense of the word, they do constitute a potential violation of privacy
interests (email accounts may not be private). However, to the extent
that an individual has provided his email address to the company for
this purpose, such mailings may have been consented to, 57 and thus
not a violation of applicable privacy law.
In addition to delivering information via websites and email, and
directing traffic to relevant websites via banner and pop-up and pop-
under ads, drug companies and other drug advertisers may collect
information about individual Internet users in order to make promotion
of their products more cost-effective. Although the popular belief is
that "on the Internet, no one knows you're a dog,"'158 in fact, there is a
surprising amount of information available on the average user's
Internet surfing habits. This information is collected, often
surreptitiously, by software called "spyware" which is often installed
without the user's knowledge or express consent along with other
156In the author's experience, pharmaceutical spam is overwhelmingly from e-
pharmacies offering to sell prescription drugs with "no prior prescription required," that is, by
prescription with no physical exam or doctor-patient relationship. These prescribing practices
are violations of the VIPPS standards established by the National Association of Boards of
Pharmacy. For a description of the VIPPS program, see National Association of Boards of
Pharmacy, Verified Internet Pharmacy Practice Sites, available at http://www.nabp.net/vipps/.
For a discussion of the VIPPS standards, see John Michael Ward, Online Pharmaceutical
Regulation: An Avenue to a Safer World, 24 J. LEGAL MED. 77, 85-90 (2003).157BILL CARMODY, ONLINE PROMOTIONS 38-39 (Wiley 2001) (advising marketers to
"create a compelling reason for someone to give you permission [to market to them] in the first
place."). Thus, drug promotion websites often offer an inducement, such as a free trial coupon,
in exchange for a visitor providing his email address for future marketing efforts. See, e.g.,
http://www.clarinex.com.
158Peter Steiner, NEW YORKER, July 5, 1993 (cited in Alfred C. Yen, Western Frontier or
Feudal Society? Metaphors and Perceptions of Cyberspace, 17 BERKELEY TECH. L. J. 1207
(2002).
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software downloads from the Web, 159 and runs silently on a user's
computer.160 This software collects data about the user's Internet usage
habits and transmits that information to a centralized database. 16' This
information can then be used to more effectively target advertisements
to the user.
DTC INTERNET ADVERTISING AND
THE DOCTOR-PATIENT RELATIONSHIP
Elements of the Doctor-Patient Relationship
Although the doctor-patient relationship has been the subject of much
scholarly attention over the years, the precise nature of the relationship
has proven elusive and incapable of precise elucidation.' 62 One popular
description of the physician-patient relationship, and the analytical
framework I shall use in this Article, is derived from the work of
prominent bioethicists Nancy Dubler and Ezekiel Emanuel.
163
According to Dubler and Emanuel, the ideal trusting physician-patient
relationship can be conceptualized as involving six elements, the "six
C's: choice, competence, communication, compassion, continuity and
(no) conflict of interest."' 64 According to Emanuel and Dubler, these
six elements are important in order to allow the therapeutic trust that is
at the core of the physician-patient relationship to flourish.165 Although
trust is not one of the six elements, it is hypothesized to be the result of
them.' 66  In examining the impact of direct-to-consumer advertising
and the Internet on the physician-patient relationship, therefore, we will
use the lens of Emanuel and Dubler's six C's.
159See Robert O'Harrow, Jr., Firm Tracking Consumers on the Web for Drug
Companies, WASH. POST, Aug. 15, 2000, at El. (describing litigation against the firm
Pharmatrax).
160Gene Koprowski, A Brief History of Advertising on the Web, FORBES CRITICAL MASS,
1999 (discussing use of "cookie" technology to track consumer behavior on the Web).
161See Tim Wu, When Code Isn't Law, 89 VA. L. REv. 679, 749 n. 259 (2003).
162The legal status of the relationship is not entirely clear, either. Courts are split on such
fundamental questions as whether a physician and a patient are in a fiduciary relationship. See
Dingle v. Belia, 749 A.2d 157 (Md. 2000); McCraw v. Mary Black Hosp., 565 S.E.2d 286
(S.C. 2002); Newman v. Sonnenberg, 81 P.34d 808 (Utah Ct. App. 2003).
163Ezekiel J. Emanuel, M.D., Ph.D. & Nancy Neveloff Dubler, L.L.B., Preserving the
Physician-Patient Relationship in the Era of Managed Care, 273 JAMA 323 (1995).
'64MId. at 323.
165See id. at 324.
166See id.
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Potential Effects of DTC Advertising
Choice
One of the primary benefits touted by proponents of consumer-oriented
prescription drug advertising is its enhancement of patient choice.
According to these commentators, advertisement of prescription drugs
adds more information into the marketplace, enhancing patient
autonomy and increasing the number of choices available to patients.
In an era when health care economics make it increasingly burdensome
for physicians to talk to patients about alternative treatment
regimens, 167 prescription drug advertising provides an alternative
source of information with which patients can become true partners in
their health care and can more effectively express their desires and
values to their physicians, 168 ultimately improving patient compliance
with treatment regimens as well as health outcomes.'
6 9
Choice is of no value, though, if not accompanied by full and
accurate disclosure of the relevant data necessary to make that
choice.' 70  Although DTC advertising on the Internet has much
promise, it has so far dangerously failed to live up to that promise by
filing to make adequate disclosures of information relevant to patients'
therapeutic choices. Scholars have criticized the quality of the
information provided by drug companies to prescribing physicians.
71
However, practicing physicians have an enormous educational
advantage over the average consumer exposed to DTC drug
advertisements. 
72
167Patient survey results show that patients are satisfied with physician responses to
questions resulting from DTC advertisements. See Aikin, supra note 117. Only 3% of patients
in 2002 reported their physician becoming "angry or upset" when asked about an advertised
drug. Id.
168Research shows that DTC advertising does in fact lead patients to seek information
from their physicians. Id. Among survey respondents who searched for more information as a
result of exposure to a DTC advertisement, 89% sought information from their own physicians,
and 25% sought information from a physician other than their own doctor. Id.169Hoen, supra note 4, at 595 ("The belief that advertising may contribute to better use of
medications seems to be one of the foundations for the [1997] FDA guidelines."). But see
Lexchin, supra note 15 (suggesting that exposure to advertisements produces irrational
behavior in both consumers and physicians).
170 MARK A. HALL, MAKING MEDICAL SPENDING DECISIONS: THE LAW, ETHICS AND
ECONOMICS OF RATIONING MECHANISMS; See also Timothy S. Hall, Bargaining with
Hippocrates: Managed Care and the Doctor-Patient Relationship, 54 S.C. L. REV. 689, 720
(2003).
171See Hoen, supra note 4, at 596.
172Encouragingly, patients surveyed by FDA rarely report visiting a physician expressly
in order to obtain an advertised drug. Aikin, supra note 117 (4% of respondents). On the other
hand, 50% of those who asked a physician about a specific advertised drug obtained a
prescription for the drug. Id. The data do not reflect the extent to which this represents a change
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Competence
Direct-to-consumer promotion of prescription drugs also has the
potential to enhance physician competence, albeit in an indirect
manner. The pharmaceutical industry is a fast-paced industry, and
many new drugs are approved for clinical use every year. 173 Physicians
face a constant barrage of new approved medications in every specialty,
and must devote substantial amounts of time to keeping current with
new trends and developments in pharmacology. Direct-to-Consumer
prescription drug advertising, by giving patients the tools with which to
communicate their needs and values to their physicians, helps
physicians keep up with new developments and with patient demand
for cutting edge pharmaceutical therapies.
Direct-to-consumer advertising also has the potential to diminish,
if not actual physician competence, at least the effect of physician
competence. The primary reason for the requiring certain drugs to be
dispensed only with a prescription is to protect the health of the patient
from potentially harmful side effects, drug interactions and other
unwanted consequences of the ingestion of prescription drugs. As
prescription drugs increasingly are viewed as lifestyle choices rather
than as medical choices, and as the Internet continues to create both
demand and desire for drugs and the ability to gratify that desire
without actually visiting a physicians and obtaining a prescription from
someone with actual knowledge of the patient's health status and the
wisdom of taking the drug in question, 174 the effective role of the
physician as gatekeeper is reduced. 175  Further, although the patient
may be empowered through information gained on the Internet to seek
out alternative treatments and to become a partner in his own health
care decisions, the danger is that the patient will demand certain
treatments because of the glowing description of those treatments'
efficacy in promotional materials, which may or may not be relevant or
applicable to the patient's individual circumstances. 176 Although there
is substantial educational value to information available through the
in physician prescribing practices, i.e., the number of patients who would have received a
prescription for the drug in question without specifically mentioning it. Id.
173The number of new drugs approved annually has doubled in the recent past. CTR. FOR
DRUG EVAL. & RES., BENEFIT V. RISK: How CDER APPROVES NEW DRUGS, at
http://www.fda.gov/cder/about/whatwedo/testtube-5 .pdf.
17 4See supra note 2 (citing to articles discussing the sale of prescription drugs on the
Internet in depth).
175Hoen, supra note 4, at 596 ("Pharmacists and physicians should set their own
priorities on the basis of the health needs of the patients they care for, not according to the
latest fashion in drug advertising.").
176See Lexchin, supra note 15.
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Internet, in the end, communications to patients or potential patients
from drug manufacturers and retailers are promotional messages, 17 7 and
patients may not have the critical skills to separate the promotion from
the data in making health care decisions. 1
78
Communication
Managed care has drastically affected the traditional doctor-patient
relationship.' 79 Doctors are continually under pressure to provide more
services at less cost, and one casualty of this pressure is communication
between doctor and patient. 18  By giving the patient the knowledge to
initiate conversations about various drug therapies, DTC advertising
has the potential to increase the efficiency of doctor-patient
communication. If patients are armed with relevant knowledge gained
from communications from the pharmaceutical industry, this relieves
some of the pressure on physicians to perform the role of educator, and
makes the patient more of a partner in his own health care decisions,
rather than a passive consumer of choices made by the physician.'
8
'
The Internet is a particularly promising medium for this educational
role, since it promises a highly individualized, interactive medium for
delivery of pharmaceutical knowledge, potentially tailored to the
individual consumer's health needs as well as his level of
comprehension and desire to learn about particular health conditions
and treatment options.
If patients are driven by promotional communications to desire
certain drugs,' 82 this may interfere with the ability of their physicians to
177See Timothy Hall, Bypassing the Learned Intermediary: Potential Liability for
Failure to Warn in Direct-to-Consumer Prescription Drug Advertising, 2 CORNELL J.L. & PUB.
POL'Y 449, 462 (1993).178See id. See also Hoen, supra note 4, at 595 ('Pharmaceutical marketing to prescribers,
dispensers and consumers may contribute to irrational use [of prescription drugs]...') (quoting
D.A. Fresle & C. Wolfheim, Public education in rational drug use, a global survey, 1997
WHO, (Action Programme on Essential Drugs, Geneva, Switzerland).
179See Emanuel & Dubler, supra note 155.
180For a discussion of the structural changes associated with managed care, see Timothy
S. Hall, Third-Party Payor Conflicts of Interest in Managed Care: A Proposal for Regulation
Based on the Model Rules of Professional Conduct, 29 SETON HALL L. REV. 95 (1998).
181For a discussion of the ethical desirability of patient autonomy in health care decision
making, see BEAUCHAMP & CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS 57-104 (5th ed.
2001). 182According to recent FDA data collected from a sample of patients, this does not seem
to be the case. See Statement of N. Ostrove, supra note 20 (4% of patients report requesting
specific drug from physician based on DTC advertisement).
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exercise independent judgment on the patient's behalf.183 Although an
ethical ideal of the physician-patient relationship is one of patient
empowerment and choice,' 84 this ideal must be tempered with the
understanding that the physician's extensive education, experience and
relatively objective judgment must be brought to bear in the decision-
making process.' 85 If promotional information available on the Internet
short-circuits that process to the extent that patients are showing up in
doctors' offices having self-diagnosed and self-prescribed, seeking only
a rubber stamp for their chosen therapy,' 86 they may be reluctant to
hear even the best efforts of the physician at communicating cheaper or
safer alternatives. Internet advertising runs the risk of supplanting the
doctor-patient relationship with a patient-advertiser relationship; a
scenario in which the doctor is relegated to therole of facilitator.
187
Compassion & Continuity
To the extent that in person doctor-patient relationships are supplanted
or supplemented with online prescribing practices that do not meet the
relevant standard of care, both compassion and continuity are adversely
affected. 188  Currently, several Internet pharmacies provide online
"consultations" in which patients can obtain prescriptions for drugs
simply by filling out an online form providing basic health
information.189 To the extent that prescription drugs are available in
this manner, in the absence of a doctor-patient relationship, continuity
of care is adversely affected. Not only might a patient believe that he is
receiving quality care when in fact he is receiving nothing more than a
rubber-stamped prescription that does not comply with the appropriate
183Philip R. Alper, M.D., Direct-to-Consumer Advertising: Education or Anathema?,
282 JAMA 1226 (1999) (describing DTC advertisements as an "end run around the cost-
containment efforts of health managers and physicians.").
184 TOM L. BEAUCHAMP, PH.D. & JAMES F. CHILDRESS, PH.D., PRINCIPLES OF BIOMEDICAL
ETHICS 57 (5th ed. 2001).
1851d. (discussion of autonomy "does not imply that this principle has priority over all
other principles ... ").
186See CEJA, infra note 184, at 124 (reiterating that physicians must comply with
principles of informed consent when faced with specific requests for advertised drugs).
187See Hoen, supra note 4, at 596 (articulating the fear that doctors and pharmacists may
be reduced to the role of adjunct to demand-creating DTC advertisements). To the extent that
individuals are willing to bypass the doctor-patient relationship to order drugs from online
pharmacies with no prescription, the ability of the health care professional to engage in an
informed consent dialogue, as recommended by the AMA, is diminished. See CEJA, infra note
184, at 123-124.188See supra note 2 (citing to articles discussing Internet prescribing practices in more
detail).
189See supra note 2 (citing to articles discussing Internet prescribing practices in more
detail).
Vol. 7. 1:1
DIRECT TO CONSUMER ADVERTISING
standard of care, a patient's existing relationship with his regular
physician may be harmed if the patient is engaging in drug-seeking
behavior on the Internet without informing the physician of this fact.
(No) Conflict of Interest
The topic of conflict of interest is a thorny one for the medical
profession generally, 190 and the pharmaceutical industry in particular.' 9
1
The history of promotion of prescription drugs to physicians is replete
with industry practices of generous gifts and subsidies to physicians,
often without an express demand for a quidpro quo response, but in the
hope that industry generosity would be repaid with physician brand
loyalty and prescribing patterns. 192  Only recently has the ethical
condemnation of the practice of industry gifts to physicians resulted in
the adoption of guidelines meant to reduce the appearance of
impropriety in this area.' 93  Even so, physicians and the medical
industry rely heavily on subsidy from the pharmaceutical industry, and
the potential for indirect pressure, if not a direct conflict of interest, still
underlies the relationship between practicing physicians and the drug
industry. Payment by drug companies to prescribing physicians or
others in a position to influence prescribing or purchasing decisions
creates an impermissible interference with the clinician's duties to the
patient.
94
The efficacy of DTC advertising might reduce the need for the
drug industry to target physicians quite so lavishly in order to create
brand loyalty. Although physicians by definition still exercise the final
say in whether or not to prescribe a particular drug, clearly DTC
advertising has resulted in a shift in power from the physician to the
patient. Patients may now go to their doctors with a preferred therapy
already in mind, 195 and may engage in active forum-shopping in order
to obtain that treatment. This reduces the incentive for physicians to
maintain an active gatekeeper function, and reduces the attractiveness
of physicians as targets of lavish promotional spending by drug
companies. Further, the rise of Internet pharmacies and Internet
prescriptions, although condemned by much of the medical
190For a discussion of conflicts of interest in managed care, see Hall, supra note 172.
'
91See, e.g., MARC A. RODWIN, MEDICINE, MONEY AND MORALS 107-111 (1993).
'
92See Council on Ethical and Judicial Affairs, Gifts to Physicians From Industry,
available at http://www.ama-assn.org/ama/upload/mm/369/ceja-report_030.pdf [hereinafter
CEJA].193ld.
194 CEJA, supra note 184.
'
95Statement of N. Ostrove, supra note 20.
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establishment, is placing even more power in the hands of the
individual consumer, who can now obtain many, if not most,
prescription medications without the need to visit a doctor at all.
196
These developments further undercut the role of the physician as
gatekeeper and sole decision-maker in the choice of therapies, and may
result in fewer conflicts of interest as drug makers scale back their
physician advertising of certain drugs in favor of direct to consumer
advertising.
Effect of DTC Advertisement on Health Outcomes
Direct-to-consumer advertisement may have an ultimate effect on
health outcomes in several ways, all related to the quality and
completeness of the information provided, and the appropriateness of
that information to the targeted audience.
First, the use of DTC advertisement may produce a preference in
the minds of consumers for newer, more heavily advertised (and more
expensive) drugs, rather than older therapies. This is so because it is
during the first years of a drug's approval and marketing when prices
for the drug are highest; while the drug still enjoys patent protection
and generic drug manufacturers have not yet marketed alternatives.
This preference for newer therapies may also arise from the nature of
American consumerism, in which the "new and improved" is
continually being promoted, perhaps leading to an association in the
mind of the consumer between "new" and "improved."
This association is not necessarily correct in the case of
prescription drugs, however. In fact, newer drugs may be notably less
safe than their older counterparts, in part because less is known about
the clinical efficacy and proper prescribing of the new drug.197 Safety
information is not fully developed at the time a new drug is approved,
but continues to be collected as the drug is marketed. 198 Further, a new
drug therapy may not provide enhanced therapeutic efficacy compared
to a traditional alternative, or may not provide that enhanced efficacy in
all cases or for all individuals.
199
196See supra note 2.
'
97Hoen, supra note 4, at 595.
19 8Julie Bietz, Post Marketing Risk Assessment of Drug Products, CTR. FOR DRUG EVAL.
& RESEARCH, available at http://www.fda.gov/cder/present/raps 10-2002/juliebietz/.
199See That Money Show, Drug Advertising, at
http://www.pbs.org/wnet/moneyshow/cover/033001 .html.
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Further, the prevalence of DTC advertising may lead consumers to
"self-medicate, 2 ° ° procuring prescription pharmaceuticals from online
pharmacies on the basis of information obtained from marketing
websites and emails, without seeking the advice of a trained
physician.20 1 However, the lack of adequate information may make
this practice risky or positively dangerous for consumers.
202
Evidence suggests that patient exposure to DTC advertising may
have negative health consequences as well. In one study of HIV-
positive gay men in San Francisco, the investigators found a correlation
between an individual's exposure to DTC advertisement for HIV
treatments and that individual's perception on the seriousness of HIV
infection.203 Those with more exposure to DTC advertisements tended
to view HIV infection as less serious. 204  These data suggest that
exposure to such advertisements may direc t ly affect in individual's
decision to engage in unsafe sexual behavior.
205
PROPOSALS FOR REGULATION OF
ONLINE DTC ADVERTISING
The goal of regulation of direct-to-consumer advertising should be the
protection and preservation of the physician-patient relationship. In
fact, much of the regulation of the relationship between pharmaceutical
companies and physicians has this same goal, in the form of protection
of physicians from undue conflicts of interest. 20 6  We have already
mentioned the history of unethical "gifts" and other subsidies to
2
°°See Study: E-Pharmacies Could Harm Consumers' Health, Reuters Internet Report,
April 8, 2003.20 1Many of the emails touting e-pharmacy services emphasize the fact that no physician
visit or "prior prescription" is required to obtain drugs.
2 21d. (reporting that despite the existence of some Internet pharmacy practice standards,
current e-pharmacies are failing to comply with good practices, and that more than half
provided either no information or too little information to be of benefit to consumers). Study:
E-Pharmacies Could Harm Consumers' Health, supra note 200.203Jeffrey D. Klausner, et al., Are HIV Drug Advertisements Contributing to Increases in
Risk Behavior Among Homosexual Men in San Francisco, 2001?, 16 AIDS 2349 (2002).2041d. ("HIV-Positive homosexual men who saw advertisements at least weekly were six
times more likely to believe that HIV was less serious compared with HIV-positive
homosexual men who saw advertisements less frequently[.]").2051d. at 2350 ("HIV-positive respondents with frequent advertisement exposure more
often reported unprotected anal sex compared with HIV-positive respondents with infrequent
exposure.").
206For an extensive discussion of the phenomenon of conflicts of interest in medical
practice, see MARC A. RODWIN, MEDICINE, MONEY AND MORALS: PHYSICIANS' CONFLICTS OF
INTEREST (1993).
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physicians from drug manufacturers. 20 7  A prohibition of DTC
advertising would prevent some of the abuses and detriments described
above. It would certainly curtail the efforts and the spending of the
major pharmaceutical manufacturers on DTC advertising. However,
such a regulatory response is suboptimal for several reasons. First, it
would not prevent or effectively prohibit all Internet advertising. The
Internet effectively blurs national borders, and makes national laws of
questionable efficiency in regulating online behavior.20 8 Second, a ban
on DTC advertising on the Internet would be against the current trend
of increased information flow to consumers. Health information is one
of the leading uses of the Intemet,2°9 and other authorities are
considering relaxing rather than tightening restrictions on
communications with consumers of prescription drugs.210  Finally, a
ban, while not eliminating all the poor information flowing into the
marketplace, 211 would eliminate the possibility of use of the Internet to
enhance the physician-patient relationship through increasing the
patient's ability to exercise his autonomy and increasing the level of
discourse that is possible between physician and patient about the
patient's treatment options. The Internet also has the possibility of
2
°7Id. at 107-110.
208Similar problems exist in attempts to regulate online casinos and mass e-mailers, both
of whom often operate from outside United States jurisdiction for the purposes of avoiding U.S.
jurisdiction. See generally Lawrence G. Waters, The Law of Online Gambling in the United
States:- A Safe Bet, or Risky Business?, 7 GAMING L. REV. 445, 446 (2003) ("Many hosting and
software development companies have also been willing to roll the 'legal dice' by creating
offshore casinos or sports betting sites and providing them bandwidth."); Paul Schiff Berman,
The Globalization of Jurisdiction, 151 U. PA. L. REV. 311, 355 (2002) ("Gambling, child
pornography or 'spam' operations targeting users in one jurisdiction will often locate their
servers elsewhere.").209See John Blum, Internet Medicine and the Evolving Legal Status of the Physician-
Patient Relationship, 24 J. LEGAL MED. 413, 415 (2003) ("More than 52 million adults in the
United States have searched the World Wide Web for health and medical information.").210While only the United States and New Zealand currently allow DTC marketing of
prescription drugs, the European Union is considering a proposal to allow limited promotion of
prescription drugs in the categories of HIV/AIDS treatments, diabetes treatments and asthma.
See Vanessa Fuhrmans & Gautam Naik, Pushing Pills: In Europe, Prescription-Drug Ads Are
Banned - and Health Costs Lower, WALL ST. J., March 15, 2002, at B 1 (describing pressure to
relax regulation of drug marketing from drug companies and the Internet, and describing a
proposed EU proposal to test DTC marketing); Drugs on Net opens health-care debate, Bus.
&FIN. UK 22 (2002) (describing British regulations prohibiting DTC marketing and the current
controversy over increasing the ability of drug companies to provide information to patients);
Colin Meek, Direct-to-consumer advertising (DTCA) of prescription medicines: second
quarterly update-April to June 2002, PROPOSED MODIFICATIONS OF DIRECTIVE 2001/83/EC ON
THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE, ARTICLE 88
(2002).2 1 Fuhrmans & Naik, supra note 218 ("the Internet has already made the ban [on drug
marketing to consumers] somewhat moot...").
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reducing the burden on physicians to educate their patients about
treatment alternatives, including the alternative of prescription drugs.
Potential FDA Regulation of DTC Advertising
The FDA should continue its role as the primary regulator of direct to
consumer advertising of prescription drugs. The letter of agreement
between the FDA and FTC establishes a comprehensible and workable
sharing of authority, and is commendable to the extent it prevents
overlapping enforcement efforts212  or conflicting regulatory
requirements. However, the FDA should reexamine its current
regulatory scheme with respect to prescription drugs and make several
changes.
The Internet, with its interactivity and opportunities for
customization of information to the needs of the individual seeking it,
can actually be a better medium for the complex information related to
213prescription pharmaceuticals. However, regulatory attention is
needed in order to help users navigate the sea of information available
on the Internet. In considering how to apply existing regulations, and
whether to adopt new regulations, I suggest that the FDA be guided by
the following three principles:
1. The FDA should explicitly take account of the Internet's
potential for interconnectivity, multimedia and other
enhancements to either print or broadcast advertisements; 214
2. The FDA should explicitly consider the implications of
the fair balance, major statement and adequate provision
rules in the online media; and
212Letter of Understanding, supra note 11, at 7287.213See, e.g., Kristen Green, Marketing Health Care Products on the Internet: A Proposal
for Updated Federal Regulations, 24 AM J.L. & MED. 365 (1998); See also Shane M. Ward,
WLF and the Two-Click Rule: The First Amendment Inequity of the Food and Drug
Administration's Regulation of Off-Label Drug Use Information on the Internet, 56 FOOD &
DRUG L.J. 41,42 (2001) (noting that the hyperlinking capability of the Internet "potentially
could offer capabilities superior to paper-based media for the purposes of presenting a complete
and unbiased scientific perspective."); Noah, supra note 24, at 148 (noting that the existing
brief summary requirement in print ads "substantially increases the cost" of such ads to the
sponsor).2 14See, e.g., Ward, supra note 205 (advocating that the FDA regulations governing
dissemination of information regarding off-label uses of prescription drugs be revised, or
specific guidance be issued, taking account of the unique features of the Internet, which
provides a low-cost, effective medium for such dissemination).
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3. The FDA should encourage the final decision whether to
take a prescription drug to be made by a patient and his
physician in the context of a healthy physician-patient
relationship.
FDA should explicitly take account of the Internet's potential for
interconnectivity, multimedia and other enhancements to either print or
broadcast advertisements
To date, the position of both the FDA and FTC has been that Internet
advertisements are adequately regulated under existing schemes.
215
While this position contains a kernel of truth; namely, that fraud is
fraud, whatever the medium,216 the unique characteristics of the
Internet deserve specific regulatory consideration, just as the specific
characteristics of other media have generated specific regulatory
approaches. While the underlying structure of the regulatory scheme is
sound and provides a framework for regulation of online promotion, the
FDA should explicitly articulate how the regulatory requirements are to
be applied in the online medium. Although the FTC has provided some
guidance to online advertisers in other industries, the FDA has to date
not provided any guidance to industry addressing Internet promotion of
prescription drugs.
Second, the Internet can enhance other forms of advertisements by
acting as a repository for further information. Data collected by the
FDA show that a significant percentage of those who seek additional
information after viewing a DTC advertisement seek that information
on the Internet. 217  The current regulatory scheme, by allowing the
Internet to be a repository of warnings concerning the drug being
advertised,2' 8 potentially threatens the balance of print and broadcast
advertisements. There are no guarantees that individuals will seek out
the warnings posted on the Internet and other sources that are alluded to
in broadcast advertisements, and substantial evidence in the informed
consent literature suggesting that they will not. Further, warnings on
the Internet may be diluted in effect by exposure to further promotional
material. The FDA must be careful in enforcing, not only the adequate
2 15Letter of Understanding, supra notes 11-13.
21 6Noah, supra note 24, at 154 ("one should not exaggerate the supposed uniqueness" of
the Internet.).21 7See Kathryn J. Aikin, Direct-To-Consumer Advertising of Prescription Drugs: Patient
Survey Results, FOOD & DRUG ADMIN. (2002) (38% of patients who seek additional information
turn to the Internet for that information).2 18See Broadcast Guidance, supra note 25.
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provision requirement, but also the fair balance requirement in
broadcast advertisements.
Currently, the FDA has insufficient resources to police the
advertisement of prescription drugs directly to consumers. 219 The life
cycle of a drug advertisement or promotional campaign is typically
short, and the lack of prior review of advertisements guarantees that the
FDA's enforcement mechanism will be limited to ordering
manufacturers to pull misleading or fraudulent advertisement after it
has had its impact on the marketplace.
The FDA should explicitly consider the implications of the brief
summary, fair balance, major statement and adequate provision rules in
the online media
Existing regulatory requirements are aimed at balancing the levels of
promotion and warning provided to viewers of the advertisement, and
should ideally give the viewer, whether a health care professional or a
consumer, sufficient resources to critically examine whether the
advertised product is appropriate. However, these requirements are not
always clearly applicable in the online medium.
When applied to a print or broadcast advertisement, the FDA's fair
balance requirement can be considered in light of a finite document - a
one or two page print layout, a thirty-second television or radio ad, or a
telephone script. However, on the Internet, the boundaries of the
advertisement are not clearly delineated, and the requisite fair balance
is unclear. Is the website's home page, or a small banner ad on a health
portal site, to be examined for fair balance on its own? Or must fair
balance be assessed with respect to each banner advertisement and each
page of the manufacturer's website?
Internet website advertisements should be treated as print
advertisements, rather than under the liberalized "adequate provision"
rules for broadcast ads, if the Internet site is treated as a whole. Just as
print ads must reproduce the entire approved package labeling as part
of the ad,220 there is no reason why the package labeling cannot be
provided as part of the Internet website. However, smaller
advertisements could be treated as analogous to a broadcast ad, with
adequate provision made for delivery of the package labeling. Even a
219See Council on Ethical and Judicial Affairs of the American Medical Association,
Direct-to-Consumer Advertisements of Prescription Drugs, 55 FOOD & DRUG L.J. 119 (2000)
(advocating health care professionals' involvement in policing DTC advertisements).220
But see criticism above that this risk information inadequately informs consumers, as
opposed to physicians, of the actual risks of the drug. Does the "fair balance" rule, in
combination with the "brief summary" rule, work to increase this protection?
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banner ad can contain a link to the website containing the package
labeling, and a toll-free number to contact for more information. With
rotating banner ads, more text can be included, such as the "see your
physician for more information" language from the Broadcast
Guidance.22'
Any regulation targeted at Internet advertising must be flexible
enough to take account of changes in the capabilities of the medium.222
For example, the Internet was originally a medium which primarily sent
text messages from computer to computer. 223  As the bandwidth
available to Internet users has grown, graphical media and animations
became more and more common. 224 Lately, the advent of consumer-
oriented DSL and cable modem technology has made it possible to
stream video over the Internet.225 It has been predicted that some day,
Internet connections will be able to transmit full-screen, broadcast-
quality video streams. 22 6 These changes have had enormous impact on
the types of promotional messages and activities that are possible on
the Internet, and no doubt the future will bring others, as yet
unanticipated changes that will pose new challenges for regulators.
As an example of the regulation of Internet technology to enhance
consumer understanding and critical evaluation of promotional
materials, the FDA might choose to prohibit use of "framing"
technologies on health care websites 227 This recommendation aims at
preventing consumer confusion when a promotional website links to
material on off-site servers. A "framed" web page opens a new web
page only in part of the user's computer monitor; other parts of the
screen still display material from the linking site. Thus, a drug
company could link to a professional society, charitable foundation, or
221See Broadcast Guidance, supra note 25.222Green, supra note 205, at 367-368.
223Int'l Trademark Ass'n, The Intersection of Trademarks and Domain Names - INTA
"White Paper", 87 TRADEMARK REP. 668 (1997) (In the 1980s, "the internet was impractical
for mass consumer participation because it was a medium that allowed for transmission of text
only ... ").224Peter Yu, Symposium-Bridging the Digital Divide: Equality in the Information Age:
Introduction, 20 CARDozo ARTS & ENT. L.J. 1 (2002) ("With the increasing use of interactive
graphics and multimedia technologies, ... high-speed Internet access may be needed to access
information....").
225Beth Simone Moveck, Designing Deliberative Democracy in Cyberspace: The Role of
the Cyber-Lawyer, 9 B.U. J. Sci. & TECH. L. 1 (2003) ("With the development of improved
streaming video over Internet technologies, the cost of video conferencing is coming down...").
2 6 See, e.g., Aaron Hurowitz, Copyright in the New Millenium, Is the Case Against
Replay TV a New Betamax for the Digital Age?, 11 CoMMLAW CONSPECTUS 145, note 208
(2003) ("In the future, consumers will be equipped with ultrafast home Internet connections
that will allow for the real time upload and download of broadcast-quality video...").227Green, supra note 205, at 384-385.
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scientific journal website discussing the product being promoted (but
not subject to FDA regulations of promotional materials), while
appearing to the visitor that the material being viewed is still part of the
manufacturer's website. Banning the use of framing technology would
be fairly easy to monitor by visiting the websites in question or
examining the HTML coding of those sites; and would help consumers
to accurately evaluate the information they are being provided by
making clear the source of that information.
FDA regulations do not currently require sufficient disclosure to
consumers of the health risks of prescription drugs. Although the brief
summary and adequate provision requirements ensure that consumers
at least have access to relevant technical data concerning a drug, this
technical disclosure is insufficient to balance the florid praise and
encomiums heaped on an advertised drug in the main portion of the
advertisement.
The FDA should work with international organizations and other
governments to internationalize the regulation of prescription drug
advertising. A persistent problem with the regulation of the Internet is
its transnational nature. A website hosted in South America is no more
difficult to access than a website hosted in the same building as the
user's computer, provided adequate infrastructure is in place to connect
to the Internet. Thus, a significant danger exists that, no matter what
regulation is put in place to govern the promotional activities of
websites and companies within the US, international websites will still
expose American citizens to false and misleading promotional
materials.228
There is probably no way to entirely eliminate the problem of
offshore Internet sites. As with the casino gaming industry, fly-by-
night operators will be able to quickly set up and tear down sites to
evade regulation. However, there are some actions that could help
minimize the problem. First, the US government can work with
international bodies and other countries to establish joint enforcement
efforts and increase cooperation. Second, the FDA and FTC can help
educate US consumers on the credibility of health claims made by e-
228Of course, there has always been some chance that an American audience might have
access to information published overseas which includes labeling information not approved by
the FDA. Noah, supra note 24, at 154 ("the FDA has never before suggested that print
advertisements in foreign publications should comply with its brief summary requirements
simply because some consumers in the United States subscribe to these newspapers and
magazines.") However, the potential reach of the Interet is potentially much greater, and there
may be insufficient signal to the reader that the information he is accessing is not intended for
an American audience.
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pharmacies, and can help consumers choose reliable online sources for
prescription drugs if online purchasing meets the consumers' needs.
Finally, the FDA and FTC can work with customs and postal
authorities to try to intercept at least some percentage of shipments of
illegal prescription drugs into the United States.
In addition to the enforcement activities described above, tort law
perhaps could help reduce the threat of fraudulent international
promotional and sales activity. Commentators have explored
expansion of tort law to encourage drug manufacturers to exercise due
care to ensure that the companies to whom they sell prescription drugs
for resale are not engaging in fraudulent or unethical behavior in selling
to the public. 229 Since most pharmaceutical companies have a presence
in the United States, they are subject to tort actions brought by
individuals harmed by offshore sales of drugs in a way that the sellers
are not. If the manufacturers of prescription drugs have a disincentive
to provide drugs for resale to e-pharmacies engaging in unethical or
fraudulent business practices, this would reduce the incidence of such
sales into the United States.
The FDA should encourage the final decision whether to take a
prescription drug to be made by a patient and his physician in the
context of a healthy physician-patient relationship.
Careful and thoughtful regulation of Internet drug promotion can help
capture the benefits of the Internet for prescription drug users, while
minimizing the detrimental effects. Access to carefully balanced
informational material can lead to increased awareness of and
responsibility for one's own health care, and improve communication
and compliance with treatment regimens. Information provided by
drug manufacturers can help supplement information provided by
physicians and other treating professionals, and the Internet's
interactivity and communications tools can tailor information to the
needs and values of each individual. Regulators must take care that
promotional materials do not eclipse or supplant the traditional doctor-
patient relationship, but merely enhance and complement it.
229Bryce A. Jensen, Note, From Tobacco to Health Care and Beyond: A Critique of
lawsuits Targeting Unpopular Industries, 86 CORNELL L. REv. 1334 (2001); Richard Ausness,
Will More Aggressive Marketing Practices Lead to Greater Tort Liability for Prescription
Drug Manufacturers?, 37 WAKE FOREST L. REv., 97 (2002) (arguing against use of tort law to
discourage overly aggressive marketing).
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Should Tort Play a Role in Regulation of DTC Advertising?
Despite the encouragement of several critics of the Learned
Intermediary Rule, courts have been reluctant to recognize the
substantially changed circumstances relating to the sale and
consumption of prescription drugs, but instead articulate an exception
to the LI Rule. Tort should play a larger role in the regulation of direct-
to-consumer prescription drug advertising, including advertising on the
Internet. Even with the best of intentions, the FDA does not possess
sufficient enforcement resources to police Internet advertising for
violations of regulatory requirements or violation of basic fairness.
Tort has the potential to create a legion of private attorneys general,
who will be empowered to hold manufacturers accountable for failure
to provide adequate information about a particular drug product.
Although the tort system is certainly an imperfect regulatory vehicle, it
can serve as a valuable adjunct to regulation by the FDA. Tort also has
the advantage of providing for compensation of those injured by drugs
insufficiently described in promotional materials, providing a
retrospective remedy as well as the prospective remedies of the FDA.
Although tort is a valuable regulatory tool, it cannot achieve its
promise without changes in the current black letter law governing
failure to warn claims involving prescription drugs. Courts must
critically examine the bases for the LI Rule, and should conclude that,
where the role of the traditional physician-patient relationship is
diminished through the use of direct communication between the drug
promoter and the ultimate consumer of the drug, the justifications for
the Learned Intermediary Rule no longer apply, and the rule should be
abrogated.
In addition to abrogation of the LI Rule's protective function in
appropriate circumstances, courts must examine carefully the question
of compliance with the common law duty to warn. Because of the
limitations of FDA regulation of direct-to-consumer prescription drug
advertising, manufacturer compliance with FDA requirements should
not be an absolute defense to tort liability for failure to warn.
CONCLUSION: ACHIEVING THE PROMISE OF INTERNET
DTC ADVERTISING
The Internet holds out much promise as a cyber-community where
participants can access a virtually unlimited amount of information.
Since health is one of the most important topics to human beings, it is
no wonder that use of the Internet to search for health-related
information has boomed in the last decade. This desire on the part of
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many people to increase their knowledge of health-related issues has
spawned a plethora of drug-related websites. It is only natural that the
companies manufacturing drugs should be both interested in
promulgating information about their products and in the best position
to inform potential consumers. The Internet provides unparalleled
interactivity between the consumer and the medium and allows drug
manufacturers, merely by making information available online, to
permit users to self-select the information they desire. However, the
current regulatory environment fails to correct the perverse incentives
in the marketplace to provide inadequate, incomplete information about
drug products. When combined with the well-known phenomenon of
the bounded rationality of health care consumers, and the current ease
with which the Internet permits patients who want certain prescription
drugs to bypass the requirement of a prescription from a licensed
physician. These incentives result in the suboptimal delivery of health
information and the suboptimal delivery of, and potential overuse and
misuse of, dangerous drugs.
The legal system should act to rationally regulate the advertising
of prescription drugs over the Internet in order both to reduce the
incidence of injury or death due to the misuse of prescription drugs, and
to encourage patients to be informed consumers and active participants
in their own healthcare. This regulation takes the form of providing
counterincentives to the natural incentives of the marketplace. FDA
regulations targeted at direct-to-consumer Internet advertising should
demand that drug promoters provide a true balance of information
about their products, and not overpromote the potential benefits of the
product. Further, the FDA should take care that the Internet does not
become a dumping ground for patient warnings about dangerous drugs.
Nor should the FDA allow advertisements in other media such as
television and radio to become unmitigated glorification of the benefits
of prescription drugs. Finally, state legislatures and courts must
rationally reconsider the desirability and effect of the Learned
Intermediary Rule. While this Rule is a rational response to the
traditional doctor-patient relationship, modem alterations to that
relationship, including the advent of direct to consumer advertising,
managed care and the growth of Internet pharmacies, make the rule less
desirable than it once was, and give drug manufacturers an unearned
and undesirable immunity from responsibility for the consequences of
their promotional activities. In all of this, regulators and the law should
not lose sight of the central feature of the health care system: the
doctor-patient relationship.
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No regulatory system can possibly remove all risk from
prescription pharmaceuticals. As the Restatement of Torts has
recognized, these products are to a large extent unavoidably dangerous,
and the decision to use them consists of a risk-benefit calculus that
must be performed anew for each individual patient. While the Internet
holds out much promise for empowering patients to make this decision
on an informed basis in consultation with a competent, trusted
physician, we must take care that the marketplace does not take
advantage of individuals who, because of their illness, are predisposed
to hear the good and discount the potential bad consequences of a
particular drug therapy.
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